Forbion, a Dutch life sciences venture capital firm based in Naarden, has successfully raised over €2 billion for two new funds. The announcement was made on October 15, 2024, highlighting the firm's commitment to investing in biotechnology and life sciences. This fundraising comes on the heels of a series of successful startup exits, indicating a robust market for biotech investments. The new funds will primarily focus on opportunities within the European Union, but will also extend to other regions worldwide.